NewEdge Advisors’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

NewEdge Advisors’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5	Closed	-$136	–	4225
2025 Q3	$136	Hold	5	–	–	﹤0.01%	4022
2025 Q2	$97	Hold	5	–	–	﹤0.01%	3907
2025 Q1	$88	Hold	5	–	–	﹤0.01%	3830
2024 Q4	$120	Hold	5	–	–	﹤0.01%	3775
2024 Q3	$140	Hold	5	–	–	﹤0.01%	3702
2024 Q2	$126	Hold	5	–	–	﹤0.01%	3679
2024 Q1	$146	Hold	5	–	–	﹤0.01%	3687
2023 Q4	$122	Hold	5	–	–	﹤0.01%	3629
2023 Q3	$98	Hold	5	–	–	﹤0.01%	3367
2023 Q2	$120	Hold	5	–	–	﹤0.01%	3413
2023 Q1	$110	Hold	5	–	–	﹤0.01%	3338
2022 Q4	$0	Buy	+5	New	+$124	﹤0.01%	4090

Other funds holding BBC

KCP

Kera Capital Partners San Jose, California $1.04B AUM 52.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

MCP

Militia Capital Partners Las Vegas, Nevada $435M AUM 65.91% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MML Investors Services Springfield, Massachusetts $49B AUM 25.55% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.9% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

NewEdge Advisors's BBC Position: Q4 2025 in Review

NewEdge Advisors sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q4 2025, closing a stake of 5 shares — an estimated $136 sold.

NewEdge Advisors first reported a position in BBC in Q4 2022 and held it in 12 quarters. The position peaked at $146 in Q1 2024. 19 funds tracked by Wall St. Rank hold BBC as of Q4 2025.

NewEdge Advisors reported no remaining Virtus Biotech Clinical Trials ETF position as of Q4 2025 after selling out during the quarter.
NewEdge Advisors sold 5 Virtus Biotech Clinical Trials ETF shares in Q4 2025, an estimated $136.
NewEdge Advisors first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2022 and held it in 12 quarters.
NewEdge Advisors's Virtus Biotech Clinical Trials ETF position peaked at $146 in Q1 2024.
19 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q4 2025.

Based on NewEdge Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.